SCYNEXIS to Present Posters Highlighting Ibrexafungerp Data at Four Upcoming Scientific Meetings in September 2022GlobeNewsWire • 09/01/22
SCYNEXIS, Inc. (SCYX) CEO Dr. Marco Taglietti on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/15/22
SCYNEXIS Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/15/22
SCYNEXIS to Report Second Quarter 2022 Financial results and Provide a Corporate Update on August 15GlobeNewsWire • 08/09/22
SCYNEXIS Presents Positive Data from Phase 3 CANDLE Nested Sub-Study Investigating Ibrexafungerp in Women with Recurrent Yeast Infections Who Failed Fluconazole During the ISSVD XXVI World Congress and International Vulvovaginal Disease UpdateGlobeNewsWire • 07/19/22
SCYNEXIS to Present Data from the CANDLE Nested Sub-Study of Ibrexafungerp During the International Society for the Study of Vulvovaginal Disease (ISSVD) XXVI World Congress and International Vulvovaginal Disease UpdateGlobeNewsWire • 07/14/22
SCYNEXIS Announces Initiation of New Phase 3b Study (VANQUISH) to Evaluate Oral Ibrexafungerp as a Treatment for Complicated Vulvovaginal Candidiasis (VVC) in Patients Who Failed to Respond to Treatment with FluconazoleGlobeNewsWire • 06/23/22
SCYNEXIS, Inc. (SCYX) CEO Marco Taglietti on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/12/22
SCYNEXIS Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific MeetingGlobeNewsWire • 05/10/22
SCYNEXIS to Present New Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific MeetingGlobeNewsWire • 05/04/22
SCYNEXIS Presents Data Analyses Showing Ibrexafungerp's Potential to Fight Invasive Candidiasis and Candidemia, Including Infections Caused by Candida Auris, During the 32nd Annual European Congress of Clinical Microbiology & Infectious DiseasesGlobeNewsWire • 04/27/22
SCYNEXIS Announces Closing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and WarrantsGlobeNewsWire • 04/26/22
SCYNEXIS Announces Pricing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and WarrantsGlobeNewsWire • 04/22/22
SCYNEXIS Announces Positive Interim Data from Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potency Against Severe Fungal InfectionsGlobeNewsWire • 04/22/22
SCYNEXIS to Present Positive Interim Data from Ongoing FURI and CARES Studies at the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Being Held April 23-26 in Lisbon, PortugalGlobeNewsWire • 04/20/22
SCYNEXIS Secures Additional Commercial Insurance Formulary Coverage for BREXAFEMME® (ibrexafungerp tablets), Providing Access to an Estimated 93 Million Commercially-Insured LivesGlobeNewsWire • 04/19/22
SCYNEXIS, Inc. (SCYX) CEO Marco Taglietti on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/29/22